We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A 5,000 percent price hike for the only drug indicated for treating a specific type of parasitic infection – and one that is critical for patients with lowered immune systems – is drawing howls from the public. Read More
Antibiotics developer Cempra said Friday the FDA granted a qualified infectious disease product designation for its investigational candidate Taksta to treat acute bacterial skin and skin structure infections. Read More
The FDA granted fast track designation to a drug from Mapp Biopharmaceutical to treat the Ebola virus and to Dimension Therapeutics to treat patients with hemophilia B. Read More
Amgen is acquiring Dutch biotechnology company Dezima Pharma for $300 million plus up to $1.25 billion in milestone payments, the companies announced Wednesday. Read More
Amneal Pharmaceuticals can begin marketing its generics version of Allergan’s Alzheimer’s extended-release drug Namenda XR on Jan. 31, 2020, pending FDA approval, under an agreement reached by the two firms. Read More